Home » Clinical Trials » Solid tumors » NCT05239143
NCT05239143

A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors

Study Summary

A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.

Want to learn more about this trial?

Request More Info

Interventions

P-MUC1C-ALLO1 CAR-T cellsBIOLOGICAL
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.
RimiducidDRUG
Rimiducid (safety switch activator) may be administered as indicated.

Study Locations

FacilityCityStateCountry
University of California, Irvine Medical CenterIrvineCaliforniaUnited States
Cedars Sinai Medical CenterLos AngelesCaliforniaUnited States
University of California, San DiegoSan DiegoCaliforniaUnited States
University of California, San FranciscoSan FranciscoCaliforniaUnited States
Sarah Cannon Research Institute at HealthONEDenverColoradoUnited States
University of Iowa Hospitals and ClinicsIowa CityIowaUnited States
University of Kansas Cancer CenterWestwoodKansasUnited States
Cancer Center of KansasWichitaKansasUnited States
University of Maryland Cancer CenterBaltimoreMarylandUnited States
Dana Farber Cancer InstituteBostonMassachusettsUnited States
University of Nebraska Medical CenterOmahaNebraskaUnited States
Montefiore Medical CenterThe BronxNew YorkUnited States
MD Anderson Cancer CenterHoustonTexasUnited States
NEXT OncologySan AntonioTexasUnited States

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026